Turing Biosystems

Startup

Turing Biosystems tackles high failure rates (>50%) and high toxicity (>75%) in response to immunotherapy and cell & gene therapy, where costs can be $150k-$1M+ per patient.

Our software platform is based on a new kind of interpretable AI that uses automated reasoning, NOT machine learning or language learning models. The platform integrates clinical/biological data, analyses patient therapy responses, and designs better treatments. It is built on cutting-edge hardware, including FPGA chips.

We collaborate with leading clinicians, European gene therapy and pharma companies, and are currently negotiating pilot programs with several other governmental and institutional entities.

website